Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors

Inhibition of PARP is a promising therapeutic strategy for homologous recombination–deficient tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inhibitor (PARPi) olaparib through activation of the P-...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Discov
Main Authors: Jaspers, Janneke E., Kersbergen, Ariena, Boon, Ute, Sol, Wendy, van Deemter, Liesbeth, Zander, Serge A., Drost, Rinske, Wientjens, Ellen, Ji, Jiuping, Aly, Amal, Doroshow, James H., Cranston, Aaron, Martin, Niall M.B., Lau, Alan, O’Connor, Mark J., Ganesan, Shridar, Borst, Piet, Jonkers, Jos, Rottenberg, Sven
格式: Artigo
語言:Inglês
出版: 2012
主題:
Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7518105/
https://ncbi.nlm.nih.gov/pubmed/23103855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0049
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍